Clinical Trial Update: Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial investigating anti-cytomegalovirus treatment in relapsing ulcerative colitis patients requiring vedolizumab therapy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Vedolizumab (vedolizumab)
• anti-cytomegalovirus treatment

Snippet

Sponsor: Centre Hospitalier Universitaire de Saint Etienne | Conditions: Ulcerative Colitis, Unspecified | Phase 3 | Status: TERMINATED